Lundbeck Shares Tumble After Deutsche Bank Downgrade Cites Rexulti Risks

Shares of Danish pharmaceutical firm H. Lundbeck (HLUNb) declined more than 5% on Tuesday after Deutsche Bank downgraded the stock to Sell from Hold, citing significant risks to a key revenue stream.

Analyst Downgrade Drives Sell-Off

Analysts at Deutsche Bank lowered their rating and cut their price target on Lundbeck shares to DKK 36 from DKK 40, implying potential for further downside. The bank's valuation is based on a fiscal year 2027 price-to-earnings multiple of approximately 6x, a steep discount to its European pharmaceutical peers.

The primary concern highlighted in the note is the outlook for Rexulti, a drug that accounts for approximately 25% of Lundbeck's total revenue. The bank flagged two major headwinds for the product:

• Increased competition from rival treatment Auvelity.
• A scheduled IRA-mandated price reduction in the U.S. set for 2028.

Ad

These factors threaten to erode the performance of one of the company's most important commercial assets, according to the bank's analysis.

Technical Pressure and Market Weakness

Adding to the stock's decline is a technical factor related to its share structure. Lundbeckfond Invest A/S, the company's controlling shareholder, is conducting a voluntary exchange offer allowing A-shareholders to convert to B-shares. This process, which runs through September 16, 2026, is creating near-term dilution pressure on the B-share class, as reported by Investing.com.

A broader risk-off sentiment in global markets provided little support. U.S. and European equity indices, including Denmark's OMX Copenhagen 25, traded lower, weighing on growth-oriented sectors like pharmaceuticals.